Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.
Brain metastasis from HER2-positive breast cancer: an evolving landscape
Soffietti, Riccardo
First
;Pellerino, AlessiaLast
2022-01-01
Abstract
Trastuzumab deruxtecan is an HER 2-directed antibody-drug conjugate with ability to cross the blood-tumor barrier and activity on brain metastases. To test the activity of new drugs patient-derived xenografts (PDX) models from human brain metastases and phase 0 and window of opportunity trials are of utmost importance.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
